tradingkey.logo

Viatris Inc

VTRS
View Detailed Chart

9.900USD

+0.040+0.41%
Close 09/19, 16:00ETQuotes delayed by 15 min
11.54BMarket Cap
LossP/E TTM

Viatris Inc

9.900

+0.040+0.41%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.41%

5 Days

-0.60%

1 Month

-7.30%

6 Months

+5.10%

Year to Date

-20.48%

1 Year

-16.81%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
80 / 175
Overall Ranking
239 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Hold
Current Rating
11.035
Target Price
+11.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 634.20M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is -3.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 984.91M shares, decreasing 8.14% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 144.70M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
Ticker SymbolVTRS
CompanyViatris Inc
CEOMr. Scott A. Smith
Websitehttps://www.viatris.com/en
KeyAI